Patents Filed on Lead Compounds That Directly and Specifically Activate
WOBURN, Massachusetts, March 31 /PRNewswire/ -- Mercury Therapeutics, Inc. (MTI), a company that discovers and develops orally active protein kinase targeted drugs, announces that it has filed for patent protection on three lead compounds that directly and specifically activate AMP activated protein kinase (AMPK).
The compounds are strong candidates for further development in relation to the treatment of Type-2 Diabetes and the Metabolic Syndrome, where AMPK activation is considered to be a key therapeutic target. MTI's lead compounds bind to a sub-unit of AMPK that is unique among human protein kinases.
The three lead compounds have been tested in obese mice, maintained on a high fat diet, which displayed elevated fasting blood glucose levels and a sluggish response in a glucose tolerance test (GTT). The statistically significant test results (p<0.05) showed a lowering of fasting blood glucose levels and improved performance in a GTT, without any apparent adverse effects.
MTI's proprietary integrated AMPK discovery platform technology has been central to identifying novel chemical scaffolds that have resulted in identifying multiple AMPK activators and inhibitors, and it is continuing to produce additional active molecules.
MTI will be presenting pre-clinical data in relation to Type-2 Diabetes and Metabolic Syndrome at the Spring BIO-Europe Conference in Madrid during April 7-9, 2008.
Neal C. Birnberg, Ph.D., Mercury Therapeutics' President and CEO, said:
"MTI's program to develop an orally available AMPK activator has the
potential to re-write the rules of how Type-2 Diabetes is managed. The
mechanism of action through which AMPK normalizes metabolism will also
create markets to treat the pre-diabetic state known as Impaired Glucose
Tolerance, as well as the Metabolic Syndrome. With a continuation of the
|SOURCE Mercury Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved